Accurate detection and quantification of therapeutic oligonucleotide in biological samples is crucial for evaluating biodistribution and efficacy. However, existing methods come with significant limitations:

HYBRID-ON, our innovative ELISA-based assay, overcomes these challenges by providing a low-cost, easy-to-perform solution that is sequence-agnostic. Our assay is highly sensitive (1-1000 fmol), adaptable across various sample types and lysis conditions, and has been optimized for the detection of chemically modified oligonucleotides.

Whether working with cultured cells, tissue, or serum, HYBRID-ON streamlines detection with unparalleled efficiency